View in EDS

STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant.

Saved in:
Bibliographic Details
Title: STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant.
Authors: Gallovic, Matthew D.1 (AUTHOR), Junkins, Robert D.1,2 (AUTHOR), Sandor, Adam M.1,2 (AUTHOR), Pena, Erik S.1 (AUTHOR), Sample, Christopher J.3 (AUTHOR), Mason, Ariel K.3 (AUTHOR), Arwood, Leslee C.3 (AUTHOR), Sahm, Rebecca A.3 (AUTHOR), Bachelder, Eric M.1 (AUTHOR), Ainslie, Kristy M.1,4,5 (AUTHOR), Sempowski, Gregory D.1,3 (AUTHOR), Ting, Jenny P.-Y.1,2,4,6,7 (AUTHOR) jenny_ting@med.unc.edu
Source: Journal of Controlled Release. Jul2022, Vol. 347, p356-368. 13p.
Subjects: Flu vaccine efficacy, Influenza, Seasonal influenza, Pandemics, Ferret, Influenza vaccines, Viral shedding, Vaccine effectiveness
Abstract: The current pandemic highlights the need for effective vaccines against respiratory viruses. An ideal vaccine should induce robust and long-lasting responses with high manufacturing scalability. We use an adjuvant comprised of a Stimulator of Interferon Genes (STING) agonist incorporated in a scalable microparticle platform to achieve durable protection against the influenza virus. This formulation overcomes the challenges presented by the cytosolic localization of STING and the hydrophilicity of its agonists. We evaluated a monoaxial formulation of polymeric acetalated dextran microparticles (MPs) to deliver the STING agonist cyclic GMP-AMP (cGAMP) which achieved >10× dose-sparing effects compared to other published work. Efficacy was evaluated in ferrets, a larger animal model of choice for influenza vaccines. cGAMP MPs with recombinant hemagglutinin reduced viral shedding and improved vaccine outcomes compared to a seasonal influenza vaccine. Importantly, sustained protection against a lethal influenza infection was detected a year after a single dose of the vaccine-adjuvant. [Display omitted] [ABSTRACT FROM AUTHOR]
Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:The current pandemic highlights the need for effective vaccines against respiratory viruses. An ideal vaccine should induce robust and long-lasting responses with high manufacturing scalability. We use an adjuvant comprised of a Stimulator of Interferon Genes (STING) agonist incorporated in a scalable microparticle platform to achieve durable protection against the influenza virus. This formulation overcomes the challenges presented by the cytosolic localization of STING and the hydrophilicity of its agonists. We evaluated a monoaxial formulation of polymeric acetalated dextran microparticles (MPs) to deliver the STING agonist cyclic GMP-AMP (cGAMP) which achieved >10× dose-sparing effects compared to other published work. Efficacy was evaluated in ferrets, a larger animal model of choice for influenza vaccines. cGAMP MPs with recombinant hemagglutinin reduced viral shedding and improved vaccine outcomes compared to a seasonal influenza vaccine. Importantly, sustained protection against a lethal influenza infection was detected a year after a single dose of the vaccine-adjuvant. [Display omitted] [ABSTRACT FROM AUTHOR]
ISSN:01683659
DOI:10.1016/j.jconrel.2022.05.017